In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Quizartinib is a prescription drug; the dosage and course of treatment are deter···【more】
Release date:2026-09-30Recommended:179
Adjunctive therapy for focal-onset seizures (with or without secondary generaliz···【more】
Release date:2026-09-30Recommended:24
Cobimetinib (Cotellic) is an oral, highly selective MEK1/2 inhibitor. Cobimetini···【more】
Release date:2026-09-29Recommended:174
In the field of cancer therapy, the emergence of targeted medications has brough···【more】
Release date:2026-09-28Recommended:189
Encorafenib is an oral BRAF inhibitor. All approved indications are combination ···【more】
Release date:2026-09-24Recommended:211
Encorafenib is mainly indicated for the treatment of metastatic melanoma harbori···【more】
Release date:2026-09-24Recommended:206
Whether individuals in special populations can use orforglipron and whether dosa···【more】
Release date:2026-09-23Recommended:207
Orforglipron is taken once daily, swallowed whole, can be taken with or without ···【more】
Release date:2026-09-23Recommended:254
The most common adverse reactions of Orforglipron are gastrointestinal effects—n···【more】
Release date:2026-09-22Recommended:223
Orforglipron is not a health supplement, nor is it a weight loss medication that···【more】
Release date:2026-09-22Recommended:233
Orforglipron is a prescription drug. The dosage and duration of treatment must b···【more】
Release date:2026-09-21Recommended:250
Orforglipron is an oral, small-molecule, non-peptide glucagon-like peptide-1 (GL···【more】
Release date:2026-09-21Recommended:231